Compare AbbVie Inc (ABBV) vs JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) Price & Performance

AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with strong technical momentum showing bullish moving average signals. The company demonstrates solid revenue growth, reaching $61.16B in 2025, though net margins have compressed to 5.79%. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $2.65 exceeding the $2.59 forecast. Positive clinical trial results for ELAHERE in ovarian cancer and institutional buying activity support investor confidence.

AbbVie presents a favorable risk-reward profile with 68% analyst buy ratings and a $266.33 consensus price target offering 5.4% upside. Key opportunities include Skyrizi/Rinvoq growth offsetting Humira declines, while risks involve patent expirations in the 2030s and margin pressure. The stock's elevated P/E of 124.83 reflects growth expectations but warrants monitoring of execution against guidance.

JEPQ trades at $60.16, up 1.3% with a bullish technical signal from moving averages. The ETF employs a covered call strategy on the Nasdaq-100 to generate monthly income, with recent dividends of $0.64, $0.56, and $0.59. Media coverage highlights its role in retirement portfolios but notes performance trade-offs versus pure growth ETFs.

Outlook is mixed: strong income appeal for retirees balances against capped upside in tech rallies. Key risks include underperformance in bull markets and dependence on option premiums. Investors prioritize income over capital appreciation with this strategy.